'Biosimilar' legislation proposed in Colorado

Bill would allow pharmacists to substitute generic biotech drugs for brand-name biologicals if patient's doctor has access to the information.

Although they are not even on the market yet in the U.S., biosimilars are already taking center stage when it comes to politics.

Proposed legislation in Colorado would allow pharmacists there to substitute generic biotech drugs for brand-name biologicals if the patient's doctor has access to information about the change.

A similar bill was proposed in 2013, but, according to the Denver Business Journal, "died amid lobbying for and against the measure from big drug companies."

The big difference with the legislation then and now is that drug makers are backing the doctor notification portion of the wording. Previously, some companies argued that notifying the doctor was an unneeded step, and would prevent pharmacists from prescribint a biosimilar.

List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report